Oct, 2009

U.S.A.
News / Therapeutic Area News
New Analysis Supports Tolerability of Lexiscan® (regadenoson) Injection for Pharmacologic Myocardial Perfusion Imaging Studies
Minneapolis – October 2, 2009 – A new analysis reaffirms that Lexiscan® (regadenoson) Injection, the first selective A2A adenosine receptor agonist approved for use as a pharmacologic stress...
Read More

Sep, 2009

U.S.A.
News / Therapeutic Area News
Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody The Spirit of Giving Back
DEERFIELD, IL, September 22, 2009 – Astellas Pharma US, Inc. has announced the winners of the first annual Astellas Transplant Scholars Awards, $5,000 educational scholarships awarded to six...
Read More
U.S.A.
News / Therapeutic Area News
Astellas Celebrates the Miracle of Transplantation by Sending Five Recipients to the 2010 Rose Parade®
DEERFIELD, IL, September 15, 2009 – Astellas Pharma US, Inc. today announced the winners of the Astellas Ride of a LifetimeSM 2010 contest. The contest asked transplant recipients to submit...
Read More

Aug, 2009

U.S.A.
News / Therapeutic Area News
Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel™ DosePro™
SAN DIEGO, CA, and DEERFIELD, IL (August 3, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company and Astellas Pharma US, Inc. (“Astellas”), announced today their...
Read More
U.S.A.
News / Therapeutic Area News
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
MELVILLE, N.Y., Aug 01, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced further results from the Phase III SATURN study showing that Tarceva(R) (erlotinib)...
Read More